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Abstract 
Background: Haemolysis risk with single dose or short course primaquine was evaluated in glucose-6-phosphate 
dehydrogenase (G6PD) deficient people.
Methods: Major electronic databases (to August 2016) were searched for single or short course 8-aminoquinolines 
(8-AQ) in (1) randomized comparisons against placebo in G6PD deficient people; and (2) observational compari-
sons in G6PD deficient compared to replete people. Two authors independently assessed eligibility, risk-of-bias, and 
extracted data.
Results: Five randomized controlled trials and four controlled observational cohorts were included. In G6PD deficient 
individuals, high-dose (0.75 mg/kg) PQ resulted in lower average haemoglobin levels at 7 days (mean difference [MD] 
−1.45 g/dl, 95% CI −2.17 to −0.74, 2 trials) and larger percentage fall from baseline to day 7 (MD −10.31%, 95% CI 
−17.69 to −2.92, 3 trials) compared to placebo. In G6PD deficient compared to replete people, average haemoglobin 
was lower at 7 days (MD −1.19 g/dl, 95% CI −1.94 to −0.44, 2 trials) and haemoglobin change from baseline to day 7 
was greater (MD −9.10%, 95% CI −12.55 to −5.65, 5 trials). One small trial evaluated mid-range PQ dose (0.4–0.5 mg/
kg) in G6PD deficient people, with no difference detected in average haemoglobin at day 7 compared to placebo. In 
one cohort comparing G6PD deficient and replete people there was a greater fall with G6PD deficiency (MD −4.99%, 
95% CI −9.96 to −0.02). For low-dose PQ (0.1–0.25 mg/kg) in G6PD deficient people, haemoglobin change from 
baseline was similar to the placebo group (MD 1.72%, 95% CI −1.89 to 5.34, 2 trials). Comparing low dose PQ in G6PD 
deficient with replete people, the average haemoglobin was lower in the G6PD deficient group at 7 days (−0.57 g 
(95% CI −0.97 to −0.17, 1 trial)); although change from baseline was similar (MD −1.45%, 95% CI −5.69 to 2.78, 3 
trials).
Conclusions: Falls in average haemoglobin are less marked with the 0.1 to 0.25 mg/kg PQ than with the 0.75 mg/kg 
dose, and severe haemolytic events are not common. However, data were limited and the evidence GRADE was low 
or very low certainty.
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Background
Primaquine (PQ) has been used widely since the 1950s 
to prevent relapse from Plasmodium vivax. PQ also has a 
specific action on Plasmodium falciparum gametocytes, 
as does tafenoquine, another 8-aminoquinoline (8-AQ) 
[1]. This effect may reduce P. falciparum transmission to 
mosquitoes [2]. This reduction has no clinical benefit to 
the individual, but may prevent transmission of malaria 
and thus have public health benefits. However, 8-AQs 
can cause haemolysis in people with glucose-6-phos-
phate dehydrogenase (G6PD) deficiency. The detection 
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and classification of the genotype and phenotype of 
G6PD deficiency is complicated and understanding is 
continually developing (Fig. 1; [3]). An estimated 400 mil-
lion people worldwide carry G6PD gene mutations [4–6], 
and the relatively high prevalence of between 5 and 33% 
in the malaria endemic countries of sub-Saharan Africa 
and Asia [6] makes the drug potentially unsafe within 
these populations.
In 2010, the World Health Organization (WHO) re-
affirmed a recommendation made many years previously 
Fig. 1 G6PD classification
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for a single dose of 0.75 mg/kg of PQ to be administered 
with primary treatment for falciparum malaria to reduce 
transmission [7]. In reconsidering the risks, the WHO 
lowered the recommended single dose for gametocyto-
cidal effect to 0.25 mg/kg in 2012, and limited PQ’s use 
to areas threatened by artemisinin resistance or areas 
of low endemicity approaching elimination [8]. Then in 
2015, the policy recommendation was changed to recom-
mend use in ‘low transmission areas’ and it was explicitly 
stated that G6PD testing was not required before single 
dose use [9].
The change in policy from 0.75 to 0.25 mg/kg was based 
partly on a WHO Evidence Review Group report [10, 11] 
summarizing published literature narratively, but did not 
use standard synthesis approaches to critically appraise 
the evidence. In light of the importance of the recom-
mendation when implemented at scale, it could mean 
millions of people exposed to PQ or a related drug for 
the first time [12]. In this systematic review, a narrower 
objective was considered: to assess the risk and extent of 
haemolysis in people with G6PD deficiency given PQ or 
other 8-AQ, from existing research.
Methods
Inclusion criteria
Study designs Comparisons of single or short course 
8-AQ versus placebo given to G6PD deficient people in 
randomized trials and controlled cohort designs were 
sought. This was supplemented with comparisons of 
8-AQ given to G6PD deficient or G6PD replete people.
Participants Adults or children tested for G6PD 
deficiency.
Intervention Single dose or short course 8-AQ alone or 
added to malaria treatment. Since doses and schedules 
vary by country, any single dose regimens were included. 
The short course was defined as any regimen lasting up 
to 7 days. The results are expressed within two compari-
sons (PQ vs placebo in G6PD deficient people; and PQ 
in G6PD deficient people compared with G6PD replete 
people).
Control Comparison 1: placebo or no intervention. 
Comparison 2: PQ in G6PD replete individuals.
Outcomes Haemoglobin values at baseline and day 7. 
Absolute and percentage decline in haemoglobin.
Information sources and search strategy The following 
major electronic databases were searched using the cri-
teria in Additional file 1 to August 2016: the Cochrane 
Infectious Diseases Group Specialized Register, the 
Cochrane Central Register of Controlled Trials (CEN-
TRAL), MEDLINE, Scopus, Web of Science; EMBASE 
and LILACS. All relevant trials, regardless of language 
or publication status (published, unpublished, in press 
and in progress) were identified. The MIM Pan-African 
Malaria Conferences and the American Society of 
Tropical Medicine and Hygiene (ASTMH) (from 2004 
to 2016) were also searched for relevant abstracts of 
unpublished trials, and researchers and other experts 
in the field of malaria chemotherapy were contacted. 
The reference lists of all retrieved articles were also 
reviewed [11].
Study selection and data collection RS and OU inde-
pendently screened the results of the search strategy and 
retrieved the full text of all relevant citations. The inclu-
sion criteria were independently applied using a spread-
sheet and any discrepancies were discussed or referred 
to a third reviewer (PAG or PMG). RS and OU indepen-
dently extracted data on study methods, participants, 
interventions and outcomes, and attempted to contact 
authors where data were missing.
Risk of bias RS and OU independently assessed the risk 
of bias for each study using predefined standards based 
on the Cochrane risk of bias tool for randomized con-
trolled trials, and the EPOC criteria [15] for assessing 
risk of bias of non-randomized studies (Additional file 2). 
Each domain was categorized as ‘low’ risk of bias, ‘high’ 
risk of bias or ‘unclear’. Where the judgment was that the 
risk of bias was unclear, attempts were made to contact 
the authors for clarification. The quality of evidence was 
assessed using the GRADE approach [16].
Summary measures The results were stratified as high 
(0.75  mg/kg), medium (0.4–0.5  mg/kg) and low (0.1–
0.3 mg/kg) dose of PQ.
Percentage change in haemoglobin (Hb) concentration 
from baseline was calculated as:
This percentage change was categorized as: greater 
than −5%, greater than −10% and greater than −20%. 
Moderate and severe anaemia were defined as haemoglo-
bin less than 8 g/dl and less than 5 g/dl, respectively [17–
21]. Where the data were not provided, all recent study 
authors were contacted. The author of two trials [22, 23] 
provided additional individual patient data, which were 
included in the analysis.
The values were reported as:
  • Mean difference in average haemoglobin values at 
day 7.
  • Mean difference in percent haemoglobin value 
change between baseline and day 7.
  • Relative risk of ≥5, ≥10 or ≥20% decline in haemo-
globin concentration by day 7.
  • Relative risk of moderate (≤8 g/dl) and severe (≤5 g/
dl) anaemia at day 7.
(Hb post-treatment (measured at day 7)
−Hb pre-treatment (at baseline))/
Hb pre-treatment (at baseline).
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The dichotomous outcomes were reported as risk ratios 
(RRs) and continuous outcomes as mean differences. 
Both measures are presented with 95% confidence inter-
vals (CIs). When standard deviations were not reported 
[24], we imputed these values from comparatively sized 
trials [22].
Synthesis of results All eligible studies of primaquine 
were summarized and analysed using Review Manager 
5.3. Data were presented in tables and meta-analyses per-
formed when appropriate. In the absence of statistical 
heterogeneity, a fixed-effects model was used. A random-
effects model was used where moderate heterogeneity 
was detected but it was deemed still reasonable to com-
bine trials.
This systematic review was reported according to the 
Preferred Reporting Items for Systematic Reviews and 
Meta-analyses (PRISMA) guidelines [25, 26]. PRISMA 
checklist is provided in the Additional files 3. The review 
protocol was published a priori [3].
Results
Study selection and study characteristics
1904 unique citations were identified from the search 
(Fig. 2). 1797 were excluded after abstract screening and 
98 after applying the inclusion criteria to the full text. 
We excluded 98 studies for the reasons given in the char-
acteristics of excluded studies Additional File 4. Five 
randomized controlled trials [22–24, 27, 28] and four 
controlled observational cohorts [29–32], all published 
between 2004 and 2016, met the inclusion criteria (see 
Table  1). Eight studied primaquine, and one study avail-
able as a conference abstract studied tafenoquine. G6PD 
deficiency detection methods, phenotypes and geno-
types are summarized in Table  2. Four studies reported 
that they used the fluorescent spot test (FST) for screen-
ing [27, 29–31], and one study used the rapid test rather 
than FST [28]. Studies also reported enzyme quantifica-
tion and/or polymerase chain reaction to detect G202A/
A376G mutation [22, 23, 27, 28] or Mahidol mutation 
Fig. 2 Study selection flow diagram
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[29, 30, 32]. The reported genotypes varied across studies, 
and G6PD activity was not always measured and not con-
sistently reported, so no stratified analysis was possible.  
PQ compared to placebo in G6PD deficient individuals 
Four randomized controlled trials reported haemoglo-
bin levels [22, 23, 27, 28]. Three out of the four studies 
recruited only children and adolescents [22, 23, 27] and 
one recruited participants of all ages [28]. Three studies 
were conducted in individuals with confirmed malaria (P. 
falciparum [22, 27, 28]).
One study used high (0.75  mg/kg), medium (0.4–
0.5 mg/kg) and low (0.1–0.25 mg/kg) dose PQ [27], two 
studies used only high dose PQ [22, 23], and one used 
low dose PQ [28].
PQ in G6PD deficient compared to replete individu-
als Five randomized controlled trials [22–24, 27, 28] 
and three controlled observational cohorts [29–31] 
reported haemoglobin levels after PQ treatment. One 
of the eight studies recruited only adults [24], and 
four recruited participants of all ages [24, 28–31]. 
Table 2 G6PD detection methods, phenotypes and genotypes
FST fluorescent spot test, PCR polymerase chain reaction, RFLP restriction fragment length polymorphism (RFLP)
a Only G6PD ‘normal’ participants based on the FST test; those not normal G6PD by FST were excluded and the genotyping was done on the remainder
Study (country) Methods Results
Phenotype Genotype
Krudsood [24]
(Thailand)
Not reported G6PD normal: 134 patients
G6PD deficient: 7 patients
Not tested
Shekalaghe [22]
(Tanzania)
PCR for G202A, A376G G6PD normal: 77 patients
G6PD deficient: 30 patients
G6PD wild type: 77 patients
G6PD deficient heterozygous: 23 patients
G6PD deficient hemizygous/homozy-
gous: 7 patients
Shekalaghe [23]
(Tanzania)
PCR for G202A, A376G G6PD normal: 493 patients
G6PD deficient: 69 patients
G6PD wild type: 493 patients
G6PD deficient heterozygous: 47 patients
G6PD deficient hemizygous/homozy-
gous: 22 patients
Rueangweerayut [32]
(Thailand)
PCR RFLP for Mahidol G6PD normal (Mahidol negative with 
>80% G6PD activity): 6 patients
G6PD deficient (G6PD enzyme activity 
40–60% of normal): 6 patients
G6PD wild type: 6 patients
G6PD deficient heterozygous: 6 patients
Eziefula [27, 33]a
(Uganda)
FST; PCR for G202A/A376G G6PD normal: 373 patients
G6PD deficient: 88 patients
G6PD wild type: 373 patients
G6PD deficient heterozygous: 61 patients
G6PD deficient hemizygous/homozy-
gous: 27 patients
Kheng [30]
(Cambodia)
FST; enzyme quantification; PCR for 
Mahidol, Mediterranean, Coimbra, 
Chinese-5, and Canton
G6PD normal: 57 patients
G6PD deficient: 18 patients
G6PD wild type: 57 patients
G6PD deficient hemizygous male: 14 
patients
G6PD deficient homozygous female: 1 
patient
G6PD deficient heterozygous female: 3 
patients
Bancone [29]
(Thai–Myanmar border)
FST; enzyme quantification; PCR RFLP 
for Mahidol. Chinese-4, Canton and 
Viangchan
G6PD normal: 1226 patients
G6PD intermediate: 50 patients
G6PD deficient: 124 patients
G6PD wild type: 1226 patients
G6PD deficient hemizygous male: 39 
patients
G6PD deficient homozygous female: 5 
patient
G6PD deficient heterozygous female: 65 
patients
Ley [31]
(Bangladesh)
FST; enzyme quantification G6PD normal: 169
Mild G6PD deficiency: 5 patients
Severe G6PD deficiency: 1 patient
Not tested
Mwaiswelo [28]
(Tanzania)
Rapid test; PCR for G202A, A376G G6PD normal: 184 patients
G6PD deficient: 33 patients
Males
G6PD A wild type: 95 patients
G6PD A− hemizygous: 15 patients
Females
G6PD AA and BA wild type: 83 patients
G6PD A−A− homozygous: 5 patients
G6PD AA− and BA−heterozygous: 22 
patients
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Five studies were conducted in people with confirmed 
malaria: three of P. falciparum [22, 27, 28] and two of 
P. vivax [24, 31]. One of the eight studies [24] admin-
istered PQ as a 7-day course and the remaining seven 
studies used single dose PQ [22, 23, 27–31]. Five stud-
ies used high dose PQ [22, 23, 27, 30, 31], two used 
medium dose PQ [24, 27] and three used low dose PQ 
[27–29].
One controlled observational cohort evaluated 100, 
200 and 300 mg single dose tafenoquine [32]. This study 
recruited adults without malaria.
Risk of bias assessment The risk of bias of the nine 
included studies is summarized in Fig. 3.
Baseline characteristics Six studies were classed as low 
risk of bias [22, 27–31]; in two it was unclear; and in one 
there were baseline differences that were likely to influ-
ence the results [22].
Blinding of outcome assessors One study was low risk 
(an RCT) [22]; six studies were classed as unknown risk 
of bias; two studies did not blind outcome assessors [24, 
32].
Attrition and incomplete outcome data All studies were 
deemed to be at low risk of attrition bias.
Reporting bias and selective reporting One study was 
at high risk of reporting bias as stated outcomes were 
not reported within the results [24]. Of the five trials 
described as randomized [22–24, 27, 28], risk of bias due 
to random sequence generation and allocation conceal-
ment was low in two studies [22, 28] and unclear in the 
remaining three studies [23, 24, 27].
Certainty of evidence
Our assessment of the quality of evidence using the 
GRADE approach is presented in summary of findings 
tables (Additional files 5, 6, 7, 8, 9, 10).
High dose (0.75 mg/kg) PQ
PQ compared to placebo in G6PD deficient people Three 
randomized trials [22, 23, 27] report 0.75 mg/kg PQ ver-
sus placebo in people with G6PD deficiency, all part of 
larger trials. Numbers with G6PD deficiency were small, 
and one trial excluded those with severe deficiency [27]. 
Two trials were considered low risk of bias [22, 27], while 
one was at high risk of bias due to large baseline differ-
ences in haemoglobin concentration between groups 
[23].
Average haemoglobin values at day 7 Two trials 
reported this [22, 23], and found haemoglobin to be 
lower with PQ (MD −1.45 g/dl, 95% CI −2.17 to −0.74, 
93 participants, low certainty evidence, Fig. 4.1).
Percent haemoglobin value change between baseline and 
day Three trials reported this [22, 23, 27], and haemoglo-
bin fell further in individuals treated with PQ (mean dif-
ference −10.31%, 95% CI −17.69 to −2.92, I2 = 64%, 134 
participants, low certainty evidence, Fig. 4.2).
Risk of anaemia Two trials reported this [22, 23], with 
an 11-fold increase in the proportion of individuals with 
≥20% fall (low certainty evidence, Fig. 4.3).
Moderate and severe anaemia at day 7 Two trials 
reported this [22, 23], with an increased risk of anaemia 
defined by ≤8 g/dl by day 7, with one individual with Hb 
≤5 g/dl (low certainty evidence, Fig. 4.4).
PQ in G6PD deficient compared to G6PD replete people 
Five controlled observational cohorts evaluated changes 
in haemoglobin when 0.75 mg/kg PQ was given to people 
with and without G6PD deficiency [22, 23, 27, 30, 31].
Average haemoglobin values at day 7 Two trials 
reported this [22, 23] and on average, haemoglobin was 
lower with G6PD deficiency (MD −1.19  g/dl, 95% CI 
−1.94 to −0.44, 493 participants, very low certainty evi-
dence, Fig. 5.1).
Percent haemoglobin value change between baseline 
and day 7 Five trials reported this [22, 23, 27, 30, 31], and 
haemoglobin fell further in G6PD deficient people (MD Fig. 3 Risk of bias of included studies
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Fig. 4 High dose PQ (0.75 mg/kg) compared to placebo in G6PD deficient people
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Fig. 5 High dose PQ (0.75 mg/kg) in G6PD deficient compared to G6PD replete people
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−9.10%, 95% CI −12.55 to −5.65, I2 =  0%, 778 partici-
pants, very low certainty evidence, Fig. 5.2).
Risk of anaemia Two trials reported this [22, 23] and 
there was a 3.4-fold increase in risk for ≥20% fall (very 
low certainty evidence, Fig. 5.3).
Moderate and severe anaemia at day 7 Two trials 
reported this [22, 23] and there was increased risk of 
anaemia defined as ≤ 8 g/dl by day 7, with one individual 
with Hb ≤5 g/dl (Fig. 5.4).
Mid‑range dose (0.4–0.5 mg/kg)
PQ compared to placebo in G6PD deficient people One 
trial [27] evaluated 0.4  mg/kg PQ. This trial did not 
report haemoglobin at day 7 or risk of anaemia.
Percentage haemoglobin value change between baseline 
and day 7 One trial [27] reported this, and no difference 
was seen (MD −1.52%, 95% CI −7.73 to 4.69, one study, 
48 participants, low certainty evidence, Fig. 6).
PQ in G6PD deficient compared to G6PD replete people 
Two controlled cohort studies evaluated changes in hae-
moglobin with a mid-range dose of PQ given to G6PD 
deficient and G6PD replete people [24, 27]. The doses 
used in these studies ranged from 0.4 to 0.5 mg/kg. The 
two trials did not report risk of anaemia.
Average haemoglobin values at day 7 One trial [24] 
reported this, which was lower in people with G6PD defi-
ciency (MD −3.92 g, 95% CI −4.93 to −2.91, 71 partici-
pants, very low certainty evidence, Fig. 7.1).
Percent haemoglobin value change between baseline 
and day 7 One trial [27] reported this and found greater 
% change in G6PD deficient people (MD −4.99%, 95% CI 
−9.96 to −0.02, 113 participants, very low certainty evi-
dence, Fig. 7.2).
Low dose (0.1–0.25 mg/kg)
PQ compared to placebo in G6PD deficient people Two 
trials [27, 28] provide data for this, using a single dose of 
PQ versus placebo in people with G6PD deficiency. The 
doses in these studies ranged from 0.1 to 0.25  mg/kg. 
These trials did not report mean haemoglobin at follow-
up or risk of anaemia.
Percent haemoglobin value change between baseline 
and day 7 Two trials reported this [23, 26], with no dif-
ference seen (MD 1.72%, 95% CI −1.89 to 5.34, I2 = 38%, 
Fig. 6 Mid-range dose (0.4–0.5 mg/kg) PQ compared to placebo in G6PD deficient people
Fig. 7 Mid-range dose (0.4–0.5 mg/kg) PQ in G6PD deficient compared to G6PD replete people
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two studies, 89 participants, low certainty evidence, 
Fig. 8).
PQ in G6PD deficient compared to G6PD replete people 
Three controlled observational comparisons report doses 
ranging from 0.1 to 0.25 mg/kg [27–29]. The three trials 
did not report risk of anaemia.
Average haemoglobin values at day 7 One trial [29] 
reported this, which was lower in G6PD deficient peo-
ple (MD −0.57 g/dl, 95% CI −0.97 to −0.17, 830 partici-
pants, very low certainty evidence, Fig. 9.1).
Percent haemoglobin value change between baseline 
and day 7 Three controlled observational comparisons 
reported this [22, 23, 26] and no difference was seen (MD 
−1.45% g/dl, 95% CI −5.69 to 2.78, three studies, 1055 
participants, very low certainty evidence, Fig. 9.2).
Tafenoquine (Table 3)
Tafenoquine in G6PD deficient compared to G6PD replete 
people One controlled observational cohort compared 
average maximum fall in haemoglobin values in G6PD 
Fig. 8 Low dose (0.1–0.25 mg/kg) PQ compared to placebo in G6PD deficient people
Fig. 9 Low dose (0.1–0.25 mg/kg) PQ in G6PD deficient compared to G6PD replete people
Table 3 Changes in haemoglobin with different doses of tafenoquine (TQ) [32]
TQ 100 mg TQ 200 mg TQ 300 mg
G6PD normal G6PD deficiency G6PD normal G6PD deficiency G6PD normal G6PD deficiency
Number of participants 6 6 6 6 6 6
Average maximum decline in  
haemoglobin (g/dl) from baseline
−1.8 −1.28 −1.23 −1.83 −0.75 −2.78
Average day of maximum decline 10 10 10 10 10 9
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deficient and G6PD replete people given tafenoquine. 
300  mg (5  mg/kg) of tafenoquine produced a greater 
average maximum decline in haemoglobin over an aver-
age of 9  days in G6PD deficient than in G6PD replete 
individuals (Table  3). The average maximal decline in 
haemoglobin following 100 mg (1.67 mg/kg) and 200 mg 
(3.33 mg/kg) of TQ did not demonstrate a difference.
Discussion
In this review, comparative information about effects of 
PQ (and tafenoquine) on haemoglobin in G6PD defi-
cient people was summarized. The aim was to quantify 
the risk of adverse effects in those given single dose pri-
maquine to reduce infectiousness of P. falciparum. Few 
trials to date have addressed this issue directly, so indi-
rect evidence from trials that had the main aim of assess-
ing impact of 8-AQ on P. falciparum gametocytes was 
sought. Whilst these trials generate some useful informa-
tion on haemoglobin, they were not necessarily powered 
for the outcomes studied here.
The nine trials in this review were conducted with vary-
ing levels of methodological rigor. Nevertheless, with the 
0.75 mg/kg single dose in G6PD deficient people there is 
an average 1.45 g/dl greater fall in haemoglobin by day 7 
compared to placebo, and risks of anaemia (20% drop in 
haemoglobin) are increased 11-fold. For the mid-range 
dose of PQ in G6PD deficient compared to G6PD replete 
people, one trial reported a greater fall in haemoglobin of 
3.92 g/dl by day 7.
For the currently recommended low dose of 0.25 mg/
kg, there was no difference in the percentage fall in hae-
moglobin by day 7 in G6PD deficient people given low 
dose PQ compared to placebo. However, in one trial of 
PQ given to G6PD deficient compared with G6PD replete 
people, the average haemoglobin value at day 7 was 
0.57 g/dl lower in the deficient group. No difference was 
seen in percent change in haemoglobin between G6PD 
deficient and replete people. These data are somewhat 
reassuring, but the total number of the trials and people 
in the low dose (0.1 to 0.25 mg/kg) is few, and large falls 
in a few individuals cannot be excluded.
The lack of sufficient data prevented any analysis strati-
fied by G6PD type and enzyme activities. The reported 
genotypes varied across studies. It should be noted that 
one trial contributing to both comparisons [27, 33] 
included only G6PD ‘normal’ participants based on the 
FST test, but further genotyping showed wide variation 
in G6PD genotypes. Therefore, this study likely underes-
timated the effect in G6PD deficient participants. Indi-
vidual patient data meta-analysis is needed to explore 
variation due to phenotypic G6PD activity, genotype or 
applied diagnostic method, which is beyond the scope of 
the present analysis.
The enduring uncertainty surrounding safety, shown 
clearly by low or very low certainty of the evidence, 
should prompt further research on the effect of lower 
doses of PQ in people with G6PD deficiency, includ-
ing examining effects on the most prevalent genotypes. 
Only this additional information will enable policies 
to be based on an adequate evidence base and reassure 
national and local programme managers that the drug is 
safe to be used without prior G6PD testing.
Several studies on the safety of the currently recom-
mended single low dose of 0.25 mg/kg PQ in combination 
with artemisinin combination therapy in G6PD deficient 
individuals are ongoing (clinicaltrials.gov NCT02174900; 
NCT02654730; NCT02535767). These studies will help 
refine our understanding of the safety of PQ in G6PD 
deficient individuals. Enhanced and continuing pharma-
covigilance is needed to fully characterize the safety of 
PQ in the range of G6PD deficiency variants [34, 35].
Conclusions
The evidence assessed for this systematic review suggests 
that the lower single dose (0.1 to 0.25 mg/kg) of PQ given 
with the goal of reducing transmission of P. falciparum is less 
likely to cause haemolytic effects in people with G6PD defi-
ciency than the previous 0.75  mg/kg dose, and that severe 
haemolytic events are not very common. However, the evi-
dence is based on few trials and a small number of people. 
The roll-out and scale-up of the 0.25 mg/kg dose in countries 
without prior experience would greatly benefit from more 
reliable data demonstrating the safety of this dose.
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